In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

ANI Pharmaceuticals has commenced a Phase IV trial to compare two dosage levels of Purified Cortrophin Gel for acute gout ...

Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...

The CBD-based cream reduced UVA damage, preventing nuclear and mitochondrial DNA mutations associated with skin ageing and ...

At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...

Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.

Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

The US FDA has cleared Grifols' investigational new drug (IND) application to commence a Phase II trial of GRF312 Ophthalmic ...

AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201.

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.